Deignan Charles A.

Chief Financial OfficerClearside Biomedical, Inc. (CLSD) · full profile →Form 4 · filed Sep 13, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 13, 2023Option exercise(M)34K$0.40$14K398K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 13, 2023Option exercise(M)34K$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-049346) within minutes of acceptance. Every field above traces to the original document. Verify it directly: